Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis.

Klemm P, Hudowenz O, Asendorf T, Dischereit G, Müller-Ladner U, Lange U, Tarner IH.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04887-6. [Epub ahead of print]

PMID:
31916106
2.

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U.

Ann Rheum Dis. 2019 Nov;78(11):1576-1582. doi: 10.1136/annrheumdis-2019-215486. Epub 2019 Aug 7.

PMID:
31391176
3.

The activin-follistatin anti-inflammatory cycle is deregulated in synovial fibroblasts.

Diller M, Frommer K, Dankbar B, Tarner I, Hülser ML, Tsiklauri L, Hasseli R, Sauerbier M, Pap T, Rehart S, Müller-Ladner U, Neumann E.

Arthritis Res Ther. 2019 Jun 10;21(1):144. doi: 10.1186/s13075-019-1926-7.

4.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F; EUSTAR co-workers.

Clin Rheumatol. 2020 Jan;39(1):27-36. doi: 10.1007/s10067-019-04564-8. Epub 2019 May 20.

PMID:
31111363
5.

[Multimodal rheumatologic complex treatment of rheumatoid arthritis-a monocentric retrospective analysis].

Klemm P, Hudowenz O, Asendorf T, Müller-Ladner U, Lange U, Tarner IH.

Z Rheumatol. 2019 Mar;78(2):136-142. doi: 10.1007/s00393-019-0593-z. German.

PMID:
30715601
6.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

7.

[The rich diversity of Whipple's disease].

Sluszniak M, Tarner IH, Thiele A, Schmeiser T.

Z Rheumatol. 2019 Feb;78(1):55-65. doi: 10.1007/s00393-018-0573-8. Review. German.

PMID:
30552512
8.

Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease.

Rieth AJ, Richter MJ, Berkowitsch A, Frerix M, Tarner IH, Mitrovic V, Hamm CW.

PLoS One. 2018 Sep 20;13(9):e0203947. doi: 10.1371/journal.pone.0203947. eCollection 2018.

9.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

10.

Disease-Specific Effects of Matrix and Growth Factors on Adhesion and Migration of Rheumatoid Synovial Fibroblasts.

Lefèvre S, Schwarz M, Meier FMP, Zimmermann-Geller B, Tarner IH, Rickert M, Steinmeyer J, Sauerbier M, Rehart S, Müller-Ladner U, Neumann E.

J Immunol. 2017 Jun 15;198(12):4588-4595. doi: 10.4049/jimmunol.1600989. Epub 2017 May 12.

11.

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.

Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, Matucci-Cerinic M, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Riccieri V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA.

Rheumatology (Oxford). 2018 Mar 1;57(3):441-450. doi: 10.1093/rheumatology/kex182.

PMID:
28499034
12.

Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease.

Zhou B, Liao Y, Guo Y, Tarner IH, Liao C, Chen S, Kermany MH, Tu H, Zhong S, Chen P.

ORL J Otorhinolaryngol Relat Spec. 2017;79(3):166-177. doi: 10.1159/000452767. Epub 2017 May 3.

PMID:
28463837
13.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors.

Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

14.

The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis.

Lange U, Dischereit G, Tarner I, Frommer K, Neumann E, Müller-Ladner U, Kürten B.

Clin Rheumatol. 2016 Nov;35(11):2783-2788. Epub 2016 Apr 6.

PMID:
27053095
15.

Is osteonecrosis of the lunate bone an underestimated feature of systemic sclerosis? A case series of nine patients and review of literature.

Frerix M, Kröger K, Szalay G, Müller-Ladner U, Tarner IH.

Semin Arthritis Rheum. 2016 Feb;45(4):446-54. doi: 10.1016/j.semarthrit.2015.07.010. Epub 2015 Aug 4. Review.

PMID:
26493463
16.

[Molecular effects of physical therapy. What's new?].

Lange U, Tarner IH, Dischereit G, Müller-Ladner U.

Z Rheumatol. 2015 Apr;74(3):226-9. doi: 10.1007/s00393-014-1544-3. German.

PMID:
25854157
17.

[Modern disease-modifying antirheumatic drugs].

Müller-Ladner U, Richter K, Tarner IH.

Internist (Berl). 2015 Mar;56(3):307-14. doi: 10.1007/s00108-014-3651-2. German.

PMID:
25700648
18.

[Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Tarner IH, Albrecht K, Fleck M, Gromnica-Ihle E, Keyßer G, Köhler L, Kötter I, Krüger K, Kuipers J, Nüßlein H, Rubbert-Roth A, Wollenhaupt J, Schneider M, Manger B, Müller-Ladner U; internationalen 3e-Initiative.

Z Rheumatol. 2014 May;73(4):363-73. doi: 10.1007/s00393-013-1249-z. German.

PMID:
24590079
19.

Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.

Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sárdy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N; all participating DNSS centers.

Ann Rheum Dis. 2015 Apr;74(4):730-7. doi: 10.1136/annrheumdis-2013-204487. Epub 2014 Jan 3.

20.

[New therapy strategies].

Müller-Ladner U, Tarner IH.

Z Rheumatol. 2013 Nov;72(9):851-2. doi: 10.1007/s00393-013-1138-5. German. No abstract available.

PMID:
24193187
21.

Interferon-α abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis.

Abeler-Dörner L, Rieger CC, Berger B, Weyd H, Gräf D, Pfrang S, Tarner IH, Schwarting A, Lorenz HM, Müller-Ladner U, Krammer PH, Kuhn A.

J Rheumatol. 2013 Oct;40(10):1683-96. doi: 10.3899/jrheum.121299. Epub 2013 Sep 15.

PMID:
24037549
22.

A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis.

Koumakis E, Bouaziz M, Dieudé P, Ruiz B, Riemekasten G, Airo P, Müller-Nurasyid M, Cusi D, Matucci-Cerinic M, Melchers I, Salvi E, Strauch K, Peters A, Cuomo G, Hachulla E, Diot E, Hunzelmann N, Caramaschi P, Riccieri V, Distler JH, Tarner I, Avouac J, Letenneur L, Amouyel P, Lambert JC, Chiocchia G, Boileau C, Allanore Y.

Arthritis Rheum. 2013 Dec;65(12):3202-8. doi: 10.1002/art.38136.

23.
24.

Acute haemodynamic response to carbon dioxide hand immersion in patients with systemic sclerosis evaluated by Doppler ultrasonography.

Müller-Eschner M, Albrecht K, Tarner IH, Müller-Ladner U, Strunk J, Lange U.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):184-5. Epub 2012 Nov 29. No abstract available.

PMID:
23191999
25.

Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Dischereit G, Tarner IH, Müller-Ladner U, Lange U.

Clin Rheumatol. 2013 Mar;32(3):377-81. doi: 10.1007/s10067-012-2128-8. Epub 2012 Nov 24. No abstract available.

PMID:
23179009
26.

Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany.

Tarner IH, Erkal MZ, Obermayer-Pietsch BM, Hofbauer LC, Bergmann S, Goettsch C, Madlener K, Müller-Ladner U, Lange U.

Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):517-23. doi: 10.1055/s-0032-1321808. Epub 2012 Sep 6.

PMID:
22956254
27.

The role of corticosteroids for pain relief in persistent pain of inflammatory arthritis: a systematic literature review.

Tarner IH, Englbrecht M, Schneider M, van der Heijde DM, Müller-Ladner U.

J Rheumatol Suppl. 2012 Sep;90:17-20. doi: 10.3899/jrheum.120337. Review.

PMID:
22942324
28.

Measuring pain and efficacy of pain treatment in inflammatory arthritis: a systematic literature review.

Englbrecht M, Tarner IH, van der Heijde DM, Manger B, Bombardier C, Müller-Ladner U.

J Rheumatol Suppl. 2012 Sep;90:3-10. doi: 10.3899/jrheum.120335. Review.

PMID:
22942322
29.

[In-vitro study on dissection of inflamed synovial tissue by hydro-jet cutting].

Wagner KH, Tarner IH, Lange U.

Z Rheumatol. 2012 Oct;71(8):707-10. doi: 10.1007/s00393-012-1010-z. German.

PMID:
22911435
30.

Sensitivity and specificity of ultrasonography and low-field magnetic resonance imaging for diagnosing arthritis.

Broll M, Albrecht K, Tarner I, Müller-Ladner U, Strunk J.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4):543-7. Epub 2012 Aug 29.

PMID:
22703848
31.

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.

Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Tarner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JW, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Ostergaard M, Westhovens R, Zochling J, van der Heijde D.

Rheumatology (Oxford). 2012 Aug;51(8):1416-25. doi: 10.1093/rheumatology/kes032. Epub 2012 Mar 24.

32.

Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.

Foocharoen C, Tyndall A, Hachulla E, Rosato E, Allanore Y, Farge-Bancel D, Caramaschi P, Airó P, Nikolaevna SM, Pereira da Silva JA, Stamenkovic B, Riemekasten G, Rednic S, Sibilia J, Wiland P, Tarner I, Smith V, Onken AT, Abdel Atty Mohamed WA, Distler O, Morović-Vergles J, Himsel A, de la Peña Lefebvre PG, Hügle T, Walker UA.

Arthritis Res Ther. 2012 Feb 20;14(1):R37. doi: 10.1186/ar3748.

33.

Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype.

Dieudé P, Bouaziz M, Guedj M, Riemekasten G, Airò P, Müller M, Cusi D, Matucci-Cerinic M, Melchers I, Koenig W, Salvi E, Wichmann HE, Cuomo G, Hachulla E, Diot E, Hunzelmann N, Caramaschi P, Mouthon L, Riccieri V, Distler J, Tarner I, Avouac J, Meyer O, Kahan A, Chiocchia G, Boileau C, Allanore Y.

Arthritis Rheum. 2011 Dec;63(12):3979-87. doi: 10.1002/art.30640.

34.

Antitumor necrosis factor-α antibody-coupled gold nanorods as nanoprobes for molecular optoacoustic imaging in arthritis.

Fournelle M, Bost W, Tarner IH, Lehmberg T, Weiß E, Lemor R, Dinser R.

Nanomedicine. 2012 Apr;8(3):346-54. doi: 10.1016/j.nano.2011.06.020. Epub 2011 Jul 6.

PMID:
21740888
35.

Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease.

Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP, Tarner IH, Maurer B, Walder M, Michel B, Gay S, Smolen JS, Müller-Ladner U, Schett G, Distler O.

Ann Rheum Dis. 2011 Jul;70(7):1197-202. doi: 10.1136/ard.2010.140657.

36.

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.

Lorenz HM, Schmitt WH, Tesar V, Müller-Ladner U, Tarner I, Hauser IA, Hiepe F, Alexander T, Woehling H, Nemoto K, Heinzel PA.

Arthritis Res Ther. 2011 Mar 1;13(2):R36. doi: 10.1186/ar3268.

37.

EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research.

Beyer C, Distler JH, Allanore Y, Aringer M, Avouac J, Czirják L, Cutolo M, Damjanov N, Del Galdo F, Fligelstone K, Guiducci S, Kowal-Bielecka O, van Laar JM, Martucci-Cerinic M, Müller-Ladner U, Riemekasten G, Tarner IH, Tyndall A, Kennedy AT, Valentini G, Vettori S, Walker UA, Denton C, Distler O; EUSTAR Biobanking Group.

Ann Rheum Dis. 2011 Jul;70(7):1178-82. doi: 10.1136/ard.2010.142489. Epub 2011 Feb 1.

38.

Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis.

Dieudé P, Guedj M, Truchetet ME, Wipff J, Revillod L, Riemekasten G, Matucci-Cerinic M, Melchers I, Hachulla E, Airo P, Diot E, Hunzelmann N, Mouthon L, Cabane J, Cracowski JL, Riccieri V, Distler J, Amoura Z, Valentini G, Camaraschi P, Tarner I, Frances C, Carpentier P, Brembilla NC, Meyer O, Kahan A, Chizzolini C, Boileau C, Allanore Y.

Arthritis Rheum. 2011 Apr;63(4):1097-105. doi: 10.1002/art.30204.

39.

NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis.

Dieudé P, Guedj M, Wipff J, Ruiz B, Riemekasten G, Airo P, Melchers I, Hachulla E, Cerinic MM, Diot E, Hunzelmann N, Caramaschi P, Sibilia J, Tiev K, Mouthon L, Riccieri V, Cracowski JL, Carpentier PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y.

Ann Rheum Dis. 2011 Apr;70(4):668-74. doi: 10.1136/ard.2010.131243. Epub 2010 Dec 13.

PMID:
21149496
40.

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.

Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M; EUSTAR Group.

Ann Rheum Dis. 2011 Mar;70(3):476-81. doi: 10.1136/ard.2010.136929. Epub 2010 Nov 15.

PMID:
21081523
41.

Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!

Müller-Ladner U, Tarner IH, Hamm C, Lange U.

F1000 Med Rep. 2010 Apr 12;2. pii: 27. doi: 10.3410/M2-27.

42.

[Biologics and cardiovascular risk].

Tarner IH, Müller-Ladner U, Hamm C.

Z Rheumatol. 2010 Oct;69(8):702-6, 708-11. doi: 10.1007/s00393-009-0583-7. German.

PMID:
20862482
43.

Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.

Söderström K, Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13028-33. doi: 10.1073/pnas.1000546107. Epub 2010 Jul 6.

44.

Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population.

Wipff J, Dieudé P, Guedj M, Ruiz B, Riemekasten G, Cracowski JL, Matucci-Cerinic M, Melchers I, Humbert M, Hachulla E, Airo P, Diot E, Hunzelmann N, Caramaschi P, Sibilia J, Valentini G, Tiev K, Girerd B, Mouthon L, Riccieri V, Carpentier PH, Distler J, Amoura Z, Tarner I, Degano B, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y.

Arthritis Rheum. 2010 Oct;62(10):3093-100. doi: 10.1002/art.27607.

45.

Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts.

Neumann E, Riepl B, Knedla A, Lefèvre S, Tarner IH, Grifka J, Steinmeyer J, Schölmerich J, Gay S, Müller-Ladner U.

Arthritis Res Ther. 2010;12(3):R83. doi: 10.1186/ar3010. Epub 2010 May 12.

46.

[A wolf in sheep's clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease].

Tarner IH, Lange U, Madlener K, Classen K, Kandolf R, Sperzel J, Müller-Ladner U.

Med Klin (Munich). 2010 Apr;105(4):300-4. doi: 10.1007/s00063-010-1048-0. German.

PMID:
20455054
47.

[Interdisciplinary emergencies in rheumatic diseases].

Tarner IH.

Dtsch Med Wochenschr. 2010 Apr;135(14):683-94; quiz 695-8. doi: 10.1055/s-0030-1251920. Epub 2010 Mar 31. German.

PMID:
20358496
48.

Synovial fibroblasts spread rheumatoid arthritis to unaffected joints.

Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnäker EM, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Schölmerich J, Pap T, Müller-Ladner U, Neumann E.

Nat Med. 2009 Dec;15(12):1414-20. doi: 10.1038/nm.2050. Epub 2009 Nov 8.

49.

BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4.

Dieudé P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, Riemekasten G, Diot E, Hunzelmann N, Sibilia J, Tiev K, Mouthon L, Cracowski JL, Carpentier PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y.

Arthritis Rheum. 2009 Nov;60(11):3447-54. doi: 10.1002/art.24885.

Supplemental Content

Loading ...
Support Center